The Impact of Hemoglobin Concentration on Prognosis in Patients With Diabetic Foot: A Systematic Review and Meta-Analysis of Risk Factors for Adverse Outcomes and Clinical Management.

Am SurgApr 15, 2026 (epub)
Clinical ResearchEndocrinologyInternal Medicine (General)Infectious Diseases

Da Wang, Hui Wang, Yue Wu et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the relationship between hemoglobin concentration and adverse outcomes in 10,984 patients with diabetic foot complications. The study found that lower hemoglobin levels were significantly associated with a higher risk of amputation (OR = 0.97, P < .001), but no significant link was established between hemoglobin levels and mortality.

Key findings

  • Lower hemoglobin levels were associated with a higher risk of amputation (OR = 0.97, P < .001).
  • Amputation cases had lower hemoglobin concentrations compared to non-amputation cases (SMD = -0.14, P < .01).
  • No significant association was found between hemoglobin levels and mortality (OR = 0.99, P > .05).

Why it matters

Understanding the role of hemoglobin levels in diabetic foot patients can help clinicians assess the risk of amputation and manage overall disease burden. This knowledge may guide future interventions aimed at improving patient outcomes.

What to keep in mind

Heterogeneity was substantial across studies, and the pooled effects were small.

Source

PubMed · PMID 41983958

Published in Am Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.